Key Points
- Chief Financial Officer Christopher Ryan Sullivan sold 8,458 shares on April 29 at an average price of $13.09 for $110,715.22, cutting his stake by 48.78% to 8,880 shares; he also sold three other blocks in early April, totaling roughly 32,874 shares for about $493,266.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan and disclosed on an SEC Form 4, while Avalo's stock draws strong analyst optimism (average target $44.83) despite negative EPS and a market cap near $366 million.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,458 shares of the company's stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares of the company's stock, valued at approximately $116,239.20. The trade was a 48.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Ryan Sullivan also recently made the following trade(s):
- On Thursday, April 30th, Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11.
- On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00.
- On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total transaction of $133,807.83.
Avalo Therapeutics Stock Performance
Shares of NASDAQ:AVTX opened at $13.71 on Friday. The firm has a market cap of $366.19 million, a PE ratio of -2.39 and a beta of 0.78. The firm's fifty day moving average is $15.29 and its 200-day moving average is $16.19. Avalo Therapeutics, Inc. has a 52 week low of $3.39 and a 52 week high of $20.72.
Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. Sell-side analysts forecast that Avalo Therapeutics, Inc. will post -4.04 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have recently commented on AVTX shares. HC Wainwright lifted their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, March 25th. Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a "buy" rating and a $50.00 target price for the company. Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an "outperform" rating and a $48.00 price objective for the company. Citizens Jmp started coverage on shares of Avalo Therapeutics in a research report on Monday, April 6th. They set an "outperform" rating and a $52.00 price objective for the company. Finally, BTIG Research reaffirmed a "buy" rating and set a $40.00 price objective on shares of Avalo Therapeutics in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $44.83.
View Our Latest Research Report on Avalo Therapeutics
Institutional Investors Weigh In On Avalo Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in Avalo Therapeutics in the fourth quarter valued at $1,150,000. XTX Topco Ltd increased its stake in Avalo Therapeutics by 190.0% in the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company's stock valued at $735,000 after purchasing an additional 26,508 shares in the last quarter. Squadron Capital Management LLC bought a new stake in Avalo Therapeutics in the fourth quarter valued at $2,361,000. SummitTX Capital L.P. bought a new stake in Avalo Therapeutics in the fourth quarter valued at $3,557,000. Finally, Millennium Management LLC increased its stake in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company's stock valued at $11,985,000 after purchasing an additional 522,548 shares in the last quarter. 87.06% of the stock is owned by institutional investors.
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
